FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022101050> ?p ?o ?g. }

• W2022101050 endingPage "966" @default.
• W2022101050 startingPage "960" @default.
• W2022101050 abstract "Our previous report demonstrated that there was impairment of local cellular immunity with elevated interleukin-10 (IL-10) and undetectable IL-12 in neoplastic pleural effusion. These findings suggest that the local immune reactions favor the T-helper type 2 (Th2) pathway instead of Th1 pathway. The present study was designed to examine whether local cellular immunity could be manipulated by IL-2 and/or IL-12 treatment, and to determine their effect on the helper T-cell pathways and the cytolytic activity of the effusion-associated lymphocytes (EALs).Using malignant pleural effusions obtained from four patients suffering from adenocarcinoma of lung, we separated the tumor cells from the EALs with Ficol-Hypaque centrifugation, followed by Percoll density centrifugation. To test whether the cytolytic function of lymphocytes could be enhanced by culturing with IL-2 and/or IL-12, lymphocytes were incubated with recombinant IL-2 with/without IL-12 for 6 days. Following this, the tumoricidal activity was assessed in an overnight 5'chromium-release assay. Autologous tumor cells for measuring specific antitumor activity, Daudi cells susceptible to lymphokine-activated killer cells, and NK-susceptible K562 cells were used as target cells.After treatment in vitro with IL-2, IL-12, or IL-2 plus IL-12, the Th pathway shifted from Th2 to Th1 type (increased gamma-interferon production). To further study the effect of cytokine treatment on the cytolytic activity of EALs, it was found that after 6-day culturing, the EALs failed to kill any of the three tumor targets, whereas the 6-day cultured peripheral blood lymphocytes (PBLs) gave low level of cytotoxicity against all three tumor targets. Stimulation with IL-2 alone partially restored the immunocompetence of EALs to kill the tumor targets. Stimulation with IL-12 alone showed no significant effect on their cytolytic activity. However, IL-12 synergized with IL-2 to increase the cytolytic activity of EALs and PBLs against autologous tumor targets. This synergistic effect was not found for Daudi cells and K562 cells.These results suggest that EALs activated with IL-12 in the presence of a low concentration of IL-2, which converted the EALs from Th2 pathway to Th1 pathway, could be an alternative source of antitumor effectors for adoptive immunotherapy of cancer." @default.
• W2022101050 created "2016-06-24" @default.
• W2022101050 creator A5009798938 @default.
• W2022101050 creator A5014314211 @default.
• W2022101050 creator A5023215362 @default.
• W2022101050 creator A5029433725 @default.
• W2022101050 creator A5029783604 @default.
• W2022101050 creator A5044395466 @default.
• W2022101050 creator A5047727465 @default.
• W2022101050 date "1997-10-01" @default.
• W2022101050 modified "2023-09-23" @default.
• W2022101050 title "Cross Regulation by IL-10 and IL-2/IL-12 of the Helper T Cells and the Cytolytic Activity of Lymphocytes From Malignant Effusions of Lung Cancer Patients" @default.
• W2022101050 cites W152476411 @default.
• W2022101050 cites W1975588465 @default.
• W2022101050 cites W1977457855 @default.
• W2022101050 cites W1985981664 @default.
• W2022101050 cites W1989904564 @default.
• W2022101050 cites W2004041151 @default.
• W2022101050 cites W2049653889 @default.
• W2022101050 cites W2054161891 @default.
• W2022101050 cites W2058516438 @default.
• W2022101050 cites W2078948721 @default.
• W2022101050 cites W2079032061 @default.
• W2022101050 cites W2088645772 @default.
• W2022101050 cites W2099748840 @default.
• W2022101050 cites W2139104516 @default.
• W2022101050 cites W2236469795 @default.
• W2022101050 cites W2322553446 @default.
• W2022101050 cites W2326245275 @default.
• W2022101050 cites W249403745 @default.
• W2022101050 cites W4211010144 @default.
• W2022101050 doi "https://doi.org/10.1378/chest.112.4.960" @default.
• W2022101050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9377959" @default.
• W2022101050 hasPublicationYear "1997" @default.
• W2022101050 type Work @default.
• W2022101050 sameAs 2022101050 @default.
• W2022101050 citedByCount "40" @default.
• W2022101050 countsByYear W20221010502012 @default.
• W2022101050 countsByYear W20221010502013 @default.
• W2022101050 countsByYear W20221010502015 @default.
• W2022101050 countsByYear W20221010502016 @default.
• W2022101050 countsByYear W20221010502017 @default.
• W2022101050 countsByYear W20221010502018 @default.
• W2022101050 countsByYear W20221010502020 @default.
• W2022101050 crossrefType "journal-article" @default.
• W2022101050 hasAuthorship W2022101050A5009798938 @default.
• W2022101050 hasAuthorship W2022101050A5014314211 @default.
• W2022101050 hasAuthorship W2022101050A5023215362 @default.
• W2022101050 hasAuthorship W2022101050A5029433725 @default.
• W2022101050 hasAuthorship W2022101050A5029783604 @default.
• W2022101050 hasAuthorship W2022101050A5044395466 @default.
• W2022101050 hasAuthorship W2022101050A5047727465 @default.
• W2022101050 hasConcept C126322002 @default.
• W2022101050 hasConcept C142724271 @default.
• W2022101050 hasConcept C154317977 @default.
• W2022101050 hasConcept C202751555 @default.
• W2022101050 hasConcept C203014093 @default.
• W2022101050 hasConcept C2776256026 @default.
• W2022101050 hasConcept C2777371288 @default.
• W2022101050 hasConcept C2777701055 @default.
• W2022101050 hasConcept C2778690821 @default.
• W2022101050 hasConcept C2779634585 @default.
• W2022101050 hasConcept C3017875465 @default.
• W2022101050 hasConcept C49382859 @default.
• W2022101050 hasConcept C502942594 @default.
• W2022101050 hasConcept C55493867 @default.
• W2022101050 hasConcept C71924100 @default.
• W2022101050 hasConcept C73588182 @default.
• W2022101050 hasConcept C86803240 @default.
• W2022101050 hasConcept C8891405 @default.
• W2022101050 hasConceptScore W2022101050C126322002 @default.
• W2022101050 hasConceptScore W2022101050C142724271 @default.
• W2022101050 hasConceptScore W2022101050C154317977 @default.
• W2022101050 hasConceptScore W2022101050C202751555 @default.
• W2022101050 hasConceptScore W2022101050C203014093 @default.
• W2022101050 hasConceptScore W2022101050C2776256026 @default.
• W2022101050 hasConceptScore W2022101050C2777371288 @default.
• W2022101050 hasConceptScore W2022101050C2777701055 @default.
• W2022101050 hasConceptScore W2022101050C2778690821 @default.
• W2022101050 hasConceptScore W2022101050C2779634585 @default.
• W2022101050 hasConceptScore W2022101050C3017875465 @default.
• W2022101050 hasConceptScore W2022101050C49382859 @default.
• W2022101050 hasConceptScore W2022101050C502942594 @default.
• W2022101050 hasConceptScore W2022101050C55493867 @default.
• W2022101050 hasConceptScore W2022101050C71924100 @default.
• W2022101050 hasConceptScore W2022101050C73588182 @default.
• W2022101050 hasConceptScore W2022101050C86803240 @default.
• W2022101050 hasConceptScore W2022101050C8891405 @default.
• W2022101050 hasIssue "4" @default.
• W2022101050 hasLocation W20221010501 @default.
• W2022101050 hasLocation W20221010502 @default.
• W2022101050 hasOpenAccess W2022101050 @default.
• W2022101050 hasPrimaryLocation W20221010501 @default.
• W2022101050 hasRelatedWork W1919250809 @default.
• W2022101050 hasRelatedWork W1966641017 @default.
• W2022101050 hasRelatedWork W1987323222 @default.
• W2022101050 hasRelatedWork W2014191350 @default.
• W2022101050 hasRelatedWork W2047209980 @default.

• next